Post categorized under: Cannabis
With the Cannabis and agriculture industry increasingly competitive for labs, growers and processors, new innovation and improved practices can be the difference in delivering ROI and outlasting competitors. PathogenDx delivers a unique Microarray technology that dramatically reduces testing turnaround time, adds flexibility to how and what can be tested for, and increases efficiencies for a cleaner Cannabis future. Here are the issues Cannabis faces now, with insights to help us all compete and win.
- Olympia cannabis testing lab license suspended
Washington Liquor and Cannabis Board has suspended the certification of an Olympia cannabis testing lab. The True Northwest lab received an emergency suspension of its state certification on Tuesday and has 180 days to appeal that decision to the Cannabis Board.
The agency’s staff determined that the lab failed to meet several accreditation requirements, including not having a lab director and not having its scales properly calibrated. The lab provided incorrect results to its customers, the Board said.
- Hop Latent Viroid: Alarms over global spread of dangerous marijuana viroid
The dangerous and infectious hop latent viroid that’s been on the radar of many cannabis growers since its discovery in 2018 has spread beyond North America and is threatening to spiral out of control and cause billions of dollars in industry losses, experts are warning. Researchers are calling the viroid – which is surfacing across the world – “a hidden threat” and the “biggest concern for cannabis and hop growers worldwide.”
The only surefire way to detect Hop Latent Viroid and similar viroids harming your cannabis grow is through accurate molecular testing like PathogenDx.
- Cannabis testing lab analysis finds routine THC inflation, data manipulation
The THC potency of marijuana flower sold in legal stores in four states is routinely and systematically inflated, sometimes by as much as 25% or more, according to an independent analysis of licensed cannabis testing lab data. The analysis suggests tainted products that should have been failed for contaminants and destroyed or remediated instead was passed and eventually sold by legal retailers. In addition, confirmation that THC potency inflation is running rampant – and often unchecked – across legal U.S. marijuana markets also stands to undermine consumer confidence in product labeling.
- FDA Sends Warnings To Food Firms Selling CBD
A food firm in Nevada is on notice from the FDA for concern that some of the firm’s CBD products are in forms that are appealing to children. The FDA’s review brought concern, that with these products, there is a risk of unintended consumption of the CBD ingredient by consumers. Because of the following issues, the FDA determined that introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.
- Cannabis Regulatory Compliance Is Well Worth The Cost
While in many ways it still feels like an entirely new frontier, widespread cannabis legalization in the United States began more than a full decade ago. In the time since, it has evolved into one of the fastest growing and most robust industries in the United States, generating billions of dollars in sales each year. In the states where it’s legal, it is also one of the most heavily regulated industries.
- What’s In Illicit New York Cannabis
Some New York Cannabis products sold at unlicensed storefronts are not only illegal, but also contaminated with harmful bacteria, heavy metals and toxic pesticides, according to an industry report released last week. A medical Cannabis trade group found contaminants such as E. coli and salmonella in some products purchased at these unlicensed dispensaries.
- Many California Cannabis Companies Inflate THC Numbers: Here’s How They Can Stop Them
California’s state Cannabis & Hemp regulations and consumer habits emphasize the importance of THC content of Cannabis products. This has encouraged those California Cannabis companies with bad intentions to manipulate lab results and sell their products at a higher price.
- Has the CBD Regulatory Landscape Changed?
The regulation of CBD in the United States can be described as makeshift, and that is being generous. On a federal level, Cannabis in all shapes and forms is a Schedule I controlled substance, but no federal agency has taken charge of regulating CBD products, leaving decisions up to the individual states.
- Florida Marijuana Testing Labs Under Fire as Industry Tackles Potency Problem
The issues of inflated THC potency results and lab shopping are plaguing states with large industries, including the Florida Marijuana industry. The situation has created a public mistrust of cannabis testing labs as well as a trend among marijuana businesses to shop for labs that will give them favorable test results.
- The Cannabis Regulation Crossroads in Massachusetts
The first five years of recreational Cannabis regulation in Massachusetts revealed a handful of problems. The industry is not diverse and equitable, and cities and towns have unethically taken advantage of the regulatory leverage they can hold over marijuana businesses. The state expects to reopen its regulations for additions, subtractions and revisions sometime later this year, as the industry has many wrongs to right.